Health Economics›Waldenstroem macroglobulinemia›Maintenance after first-line therapy

Maintenance after first-line therapy

Waldenstroem macroglobulinemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CaRD Variant #01	—	R 60 107	56d	—	—	~8	~R 480 854 indirect	—
Rituximab monotherapy Variant #09 Partial	—	—	28d	~20.3 mo	—	~1	—	2

2 of 2 regimens shown